Quantcast
Last updated on April 16, 2014 at 14:42 EDT

Latest Ketolide Stories

2012-03-30 18:20:08

CHAPEL HILL, N.C., March 31, 2012 /PRNewswire/ -- Cempra Inc. (Nasdaq: CEMP), a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the treatment of bacterial infectious diseases, today announced that data will be presented at the European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) demonstrating that CEM-101 (solithromycin) is active against antibiotic-resistant strains of N. gonorrhoeae. "Solithromycin is our...

2011-10-20 07:00:00

BOSTON, Oct. 20, 2011 /PRNewswire/ -- Additional data will be presented on the mechanistic characterization of adverse events reported with the azole antifungal, voriconazole, and the ketolide antibiotic, telithromycin, at the 49th Annual Meeting of the Infectious Diseases Society of America (IDSA). The data will be presented during a poster abstract session at 12:15 to 2:15 p.m. EDT on October 21 in Poster Hall B1. Bertrand et al. had previously shown that inhibition of neuronal...

2011-09-16 06:00:00

CHICAGO, Sept. 16, 2011 /PRNewswire/ -- Cempra Pharmaceuticals today announced abstracts to be presented on its fourth generation macrolide and novel fluoroketolide antibiotic, solithromycin (CEM-101), at the 51st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), September 17 to 20, 2011, in Chicago. The abstracts provide additional data that demonstrate the safety and routes of administration of CEM-101, a new generation macrolide. CEM-101 is a fluoroketolide...

2011-04-07 07:00:00

CHAPEL HILL, N.C., April 7, 2011 /PRNewswire/ -- Cempra Pharmaceuticals Inc. today announced that Prabhavathi Fernandes, Ph.D., president and chief executive officer, will present at two upcoming CHI conferences. Dr. Fernandes will present at the Second Annual Anti-Inflammatories: Small Molecule Approaches Conference at 5 p.m. PDT, April 12, at the Hilton San Diego Resort in San Diego. Her presentation is entitled "Macrolides as a New Class of Orally Active Anti-Inflammatory Agents." Her...

2010-12-01 06:00:00

CHAPEL HILL, N.C., Dec. 1, 2010 /PRNewswire/ -- Cempra Pharmaceuticals and HiQScreen today announced the publication of research revealing the molecular mechanisms that could explain certain unique adverse events associated with the ketolide, telithromycin (Ketek(TM)), which led to its restricted use. The study also showed that Cempra's novel fluoroketolide, solithromycin (CEM-101) is unlikely to generate the adverse events seen with telithromycin. The report was published in the...

2010-11-03 06:15:00

CHAPEL HILL, N.C., Nov. 3, 2010 /PRNewswire/ -- Cempra Pharmaceuticals today announced abstracts to be presented on its novel fluoroketolide antibiotic, solithromycin (CEM-101), at the American Society of Tropical Medicine and Hygiene 59th Annual Meeting, November 3 to 7 in Atlanta. The abstracts will present new information on solithromycin's antimalarial activity. Additional data will demonstrate activity against Mycobacterium leprae. Solithromycin is a fluoroketolide belonging to...

2010-10-15 07:00:00

CHAPEL HILL, N.C., Oct. 15 /PRNewswire/ -- Cempra Pharmaceuticals today announced poster presentations on its novel fluoroketolide antibiotic, solithromycin (CEM-101), and the Company's proprietary front-loading oral dosing regimen of sodium fusidate, TAKSTA (CEM-102) at the 48th Annual Meeting of the Infectious Diseases Society of America in Vancouver, British Columbia. All presentations are scheduled for 10 a.m. to 6 p.m. PDT on Friday, October 22. Solithromycin (CEM-101) The...

2010-09-08 07:00:00

CHAPEL HILL, N.C., Sept. 8 /PRNewswire/ -- Cempra Pharmaceuticals announced that it is moving forward in its dual approach to the development of solithromycin (CEM-101), a fluoroketolide which is first of a new generation of macrolide-ketolide antibiotics for treatment of community-acquired bacterial pneumonia (CABP). Patients with CABP are currently being enrolled into a Phase 2 trial evaluating the oral formulation of solithromycin while concurrently a Phase 1 trial with the...

2010-05-18 08:15:00

CHAPEL HILL, N.C., May 18 /PRNewswire/ -- Cempra Pharmaceuticals today announced the results from two poster presentations on its novel antibiotic CEM-101, a next-generation macrolide, at the American Thoracic Society 2010 International Conference, May 14 to 19, 2010, in New Orleans. Both presentations are scheduled for 8:15 a.m. to 4 p.m. CDT on Tuesday, May 18. The two posters by Kobayashi et al. compared the anti-inflammatory activity of CEM-101 to several available macrolide...

2010-05-13 06:00:00

CHAPEL HILL, N.C., May 13 /PRNewswire/ -- Cempra Pharmaceuticals today announced the schedule of poster presentations on its next-generation macrolide, CEM-101, at the American Thoracic Society (ATS) 2010 International Conference in New Orleans, Louisiana, on May 14 to 19, 2010. Both posters will be presented during the poster session entitled "C41 Emerging Pharmacology for Chronic Obstructive Pulmonary Disease: Mechanisms and Outcomes" scheduled for 8:15 a.m. to 4:00 p.m. CDT on Tuesday,...